RxDoctor Payments Data

Sonya Thomas

Psychiatric/Mental Health · Hinesville, GANPI 1427561752

Payments from drug & device makers

$2,806in general payments, 2019–2025

Across 146 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$753
  • Neurocrine Biosciences, Inc.$495
  • AbbVie$387
  • Johnson & Johnson$321
  • Teva Pharmaceuticals USA, Inc.$207
  • Otsuka America Pharmaceutical, Inc.$166
  • plus $478 from 6 others

What the payments were for

  • Food & beverage$2,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,806 in reported general payments places this provider in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$12,483
Medicare patients
42
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole78$220,233
AustedoDeutetrabenazine26$158,296
Invega SustennaPaliperidone Palmitate34$124,481
VraylarCariprazine Hcl26$40,244
PerserisRisperidone11$32,462
CaplytaLumateperone Tosylate12$20,141
Aripiprazole77$11,396
Olanzapine170$5,918
Paliperidone ErPaliperidone27$4,645
Clorazepate Dipotassium13$3,466
Haloperidol59$3,204
Haloperidol Decanoate58$2,907
Ziprasidone Hcl43$2,469
Olanzapine OdtOlanzapine18$2,224
Oxcarbazepine49$2,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$166$220,23378 claims
Teva Pharmaceuticals USA, Inc.Austedo$207$158,29626 claims
Johnson & JohnsonInvega Sustenna$321$124,48134 claims
AbbVieVraylar$387$40,24426 claims
Indivior Inc.Perseris$77$32,46211 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$147$20,14112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Hinesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →